Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings

NCT05411237 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT05411237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2030
Enrollment
130 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related kaposi sarcoma, hiv-1-infection, kaposi sarcoma